Y Intercept Hong Kong Ltd Lowers Stock Position in IDEAYA Biosciences, Inc. $IDYA

Y Intercept Hong Kong Ltd decreased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 32.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,618 shares of the company’s stock after selling 26,415 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.06% of IDEAYA Biosciences worth $1,820,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in shares of IDEAYA Biosciences by 11.8% during the fourth quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock worth $248,344,000 after buying an additional 758,117 shares during the period. Vanguard Group Inc. lifted its position in IDEAYA Biosciences by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock worth $173,518,000 after acquiring an additional 97,116 shares during the period. State Street Corp increased its holdings in shares of IDEAYA Biosciences by 27.6% in the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after purchasing an additional 893,707 shares during the period. Baker BROS. Advisors LP raised its stake in shares of IDEAYA Biosciences by 10.5% during the fourth quarter. Baker BROS. Advisors LP now owns 3,618,826 shares of the company’s stock worth $125,103,000 after purchasing an additional 343,382 shares during the last quarter. Finally, Fiera Capital Corp lifted its holdings in shares of IDEAYA Biosciences by 32.6% during the fourth quarter. Fiera Capital Corp now owns 2,437,262 shares of the company’s stock worth $84,256,000 after purchasing an additional 599,295 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $37.28 on Friday. The business’s fifty day moving average price is $31.32 and its 200 day moving average price is $32.60. The firm has a market capitalization of $3.28 billion, a PE ratio of -23.30 and a beta of -0.09. IDEAYA Biosciences, Inc. has a 1-year low of $21.33 and a 1-year high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. The business’s revenue for the quarter was down 39.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.82) earnings per share. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -4.1 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the transaction, the chief accounting officer owned 26,466 shares in the company, valued at $1,058,904.66. This trade represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IDYA shares. The Goldman Sachs Group lifted their price objective on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, April 14th. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Tuesday, April 21st. Mizuho reduced their target price on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Guggenheim lifted their target price on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Finally, Royal Bank Of Canada dropped their price target on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research note on Tuesday. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.25.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.